Zions Bancorporation N.A. Purchases 2,907 Shares of Stryker Co. (NYSE:SYK)

Zions Bancorporation N.A. raised its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 21.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,526 shares of the medical technology company's stock after purchasing an additional 2,907 shares during the period. Zions Bancorporation N.A.'s holdings in Stryker were worth $5,950,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker in the 4th quarter worth about $25,000. Dunhill Financial LLC boosted its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $30,000. Finally, BankPlus Trust Department bought a new position in Stryker during the fourth quarter valued at approximately $33,000. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research report on Tuesday, March 4th. Truist Financial lifted their price objective on Stryker from $409.00 to $413.00 and gave the stock a "hold" rating in a report on Thursday, January 30th. StockNews.com downgraded Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Wells Fargo & Company upped their price target on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Finally, Barclays raised their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $421.90.

Remove Ads

Stryker Price Performance

SYK traded down $3.16 during trading on Friday, reaching $364.38. 1,274,307 shares of the company traded hands, compared to its average volume of 1,289,456. The company has a market cap of $139.08 billion, a P/E ratio of 46.96, a PEG ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a fifty day simple moving average of $384.08 and a 200 day simple moving average of $374.32.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company posted $3.46 EPS. On average, equities analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.